Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal triamcinolone vs bevacizumab for diabetic macular edema
IRCT20250511065685N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of triamcinolone and bevacizumab in diabetic macular edema (DME) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Started Aug 2025; status: completed.
02
Drugs
triamcinolonebevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20250511065685N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250511065685N1.